Login to Your Account



Nabi Freezes StaphVax Work After Failure; Stock Plummets

By Jennifer Boggs


Wednesday, November 2, 2005
Shares of Nabi Biopharmaceuticals plunged 71.8 percent after the company halted further development of StaphVAX pending a deeper data analysis, as the product missed its primary endpoint in a Phase III trial to treat Staphylococcus aureus-caused infections in patients with end-stage renal disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription